Avalyn Pharma (NASDAQ:AVLN) Raised to Strong-Buy at Guggenheim

Avalyn Pharma (NASDAQ:AVLN) was upgraded by stock analysts at Guggenheim to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

Other equities research analysts also recently issued research reports about the company. Evercore began coverage on Avalyn Pharma in a report on Tuesday. They set an “outperform” rating and a $51.00 price target for the company. Jefferies Financial Group initiated coverage on Avalyn Pharma in a research note on Monday. They set a “buy” rating and a $52.00 price objective on the stock. Wall Street Zen upgraded shares of Avalyn Pharma to a “hold” rating in a research note on Saturday, May 9th. Finally, Morgan Stanley started coverage on shares of Avalyn Pharma in a report on Tuesday. They issued an “overweight” rating and a $53.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Strong Buy” and a consensus target price of $59.00.

Avalyn Pharma Price Performance

Shares of AVLN opened at $26.70 on Monday. Avalyn Pharma has a 52 week low of $25.05 and a 52 week high of $32.22.

Insiders Place Their Bets

In other Avalyn Pharma news, Director Jill Carroll bought 277,778 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was purchased at an average cost of $18.00 per share, with a total value of $5,000,004.00. Following the transaction, the director directly owned 2,186,562 shares in the company, valued at $39,358,116. This trade represents a 14.55% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Sr One Capital Management, Llc bought 555,555 shares of the stock in a transaction dated Friday, May 1st. The shares were acquired at an average price of $18.00 per share, for a total transaction of $9,999,990.00. Following the completion of the purchase, the insider directly owned 2,186,562 shares in the company, valued at approximately $39,358,116. This trade represents a 34.06% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.